CHRNA10

Across TCGA pan-cancer cohorts, CHRNA10 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CHRNA10 data layer compared with 7 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CHRNA10 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRNA10 expression acts as an unfavorable survival marker, although some lineages such as PAAD and UCEC show a favorable association.

LIHC, ACC, and KIRC are the cancer types where CHRNA10 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Quartile	All	0.402	0.577	.001	66	view →
ACC	OS	Quartile	All	0.426	0.825	.001	59	view →
KIRC	DFS	Tertile	II,III,IV	0.399	0.665	<.001	55	view →
PAAD	DFS	Median	All	0.447	0.274	<.001	53	view →
COAD	OS	Median	All	0.808	0.921	<.001	43	view →
LGG	DFS	Tertile	All	0.621	0.828	<.001	35	view →
PRAD	DFS	Median	All	0.837	0.935	<.001	30	view →
UCEC	DFS	Median	All	0.725	0.569	<.001	28	view →
BLCA	OS	Quartile	II,III,IV	0.764	0.628	.012	26	view →
SCLC	DFS	Tertile	III,IV	0.637	0.322	.014	19	view →
HNSC	OS	Median	All	0.740	0.629	.007	17	view →
CHOL	DFS	Median	All	0.726	0.227	.019	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CHRNA10–LIHC (DFS)

Open the LIHC breakdown →